Retrospective Study of Severe Atopic Disease in Young Children (0-5 Years) Managed with Dupilumab Highlights Significant Comorbidities

CONCLUSIONS: Our findings reveal infrequently reported high rates of atopic and neurologic comorbidities in young children with AD and underscore the importance of coordinated inter-specialty collaboration to ensure timely access to dupilumab for these patients.

via https://pubmed.ncbi.nlm.nih.gov/41462779/?utm_source=Other&utm_medium=rss&utm_campaign=None&utm_content=1lqZ3NPYysePVKsoyz66mDSgu4veDGJwnUBS47TBQPoOuNZY5J&fc=None&ff=20260111011005&v=2.18.0.post22+67771e2